CD274 and neoplasm: Patients experience abnormal responses to inhibitors of PD-1/PD-L1 and an inflammatory reaction to immune checkpoint treatment might be confused with PD in radiographical assessments [43]; therefore, it might not be appropriate to cease treatment as soon as the tumor appears to have progressed if there are no adverse effects of the current treatment on the patient.